Epistatic interactions between Fc (GM) and FcγR genes and the host control of human immunodeficiency virus replication

Human Immunology

Volumn 73, Issue 3, 2012, Pages 263-266

  Deepe, Raymond N ^a   Kistner Griffin, Emily ^a   Martin, Jeffrey N ^b   Deeks, Steven G ^b   Pandey, Janardan P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADCC; Fc R; GM allotypes; HIV; KM allotypes

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIIA; IMMUNOGLOBULIN ALLOTYPE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; CASE CONTROL STUDY; CHROMOSOME 14; CONTROLLED STUDY; DNA SEQUENCE; EUROPEAN AMERICAN; FEMALE; GENE INTERACTION; GENETIC EPISTASIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VIRUS REPLICATION;

ADULT; ASYMPTOMATIC DISEASES; CARRIER STATE; CHROMOSOMES, HUMAN, PAIR 14; EPISTASIS, GENETIC; FEMALE; HIV; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN GM ALLOTYPES; IMMUNOGLOBULIN KM ALLOTYPES; MALE; MIDDLE AGED; RECEPTORS, IGG; VIRUS REPLICATION;

EID: 84862798995     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.12.008     Document Type: Article

References (29)

1. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000, 355:1131-1137. Collaborative Group.
2. Pereyra F., Jia X., McLaren P.J., Telenti A., de Bakker P.I., Walker B.D., et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010, 330:1551-1557. International HIV Controllers Study.
3. Hessell A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
4. Ferrari G., Pollara J., Kozink D., Harms T., Drinker M., Freel S., et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011, 85:7029-7036.
5. Jefferis R., Lefranc M.P. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 2009, 1:332-338.
6. Steinberg A.G., Cook C.E. The distribution of human immunoglobulin allotypes 1981, Oxford University Press, New York.
7. Forthal D.N., Landucci G., Bream J., Jacobson L.P., Phan T.B., Montoya B. FcγRIIa genotype predicts progression of HIV infection. J Immunol 2007, 179:7916-7923.
8. Brouwer K.C., Lal R.B., Mirel L.B., Yang C., van Eijk A.M., Ayisi J., et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 2004, 18:1187-1194.
9. Poonia B., Kijak G.H., Pauza C.D. High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS ONE 2010, 5:e15562.
10. Pandey J.P. Immunoglobulin GM and KM allotypes and vaccine immunity. Vaccine 2000, 19:613-617.
11. Pandey J.P., Elson L.H., Sutherland S.E., Guderian R.H., Araujo E., Nutman T.B. Immunoglobulin kappa chain allotypes (KM) in onchocerciasis. J Clin Invest 1995, 96:2372-2374.
12. Granoff D.M., Pandey J.P., Boies E., Squires J., Munson R.S., Suarez B. Response to immunization with Haemophilus influenzae type b polysaccharide-pertussis vaccine and risk of Haemophilus meningitis in children with the Km(1) immunoglobulin allotype. J Clin Invest 1984, 74:1708-1714.
13. Pandey J.P., Astemborski J., Thomas D.L. Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus. J Virol 2004, 78:4561-4565.
14. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002, 31:429-434.
15. Accessed 1 August 2011. http://cfar.ucsf.edu/pdf/cores/scope-criteria-11-08-2010.pdf.
16. Balbín M., Grubb A., Abrahamson M., Grubb R. Determination of allotypes G1m(f) and G1m(z) at the genomic level by subclass-specific amplification of DNA and use of allele-specific probes. Exp Clin Immunogenet 1991, 8:88-95.
17. Brusco A., de Lange G.G., Boccazzi C., Carbonara A.O. Molecular characterization of Gm(n+) and G2m(n-) allotypes. Immunogenetics 1995, 42:414-417.
18. Balbín M., Grubb A., de Lange G.G., Grubb R. DNA sequences specific for Caucasian G3m(b) and (g) allotypes: allotyping at the genomic level. Immunogenetics 1994, 39:187-193.
19. Moxley G., Gibbs R.S. Polymerase chain reaction-based genotyping for allotypic markers of immunoglobulin kappa shows allelic association of Km with kappa variable segment. Genomics 1992, 13:104-108.
20. Jiang X.M., Arepally G., Poncz M., McKenzie S.E. Rapid detection of the FcγRIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods 1996, 199:55-59.
21. Dijstelbloem H.M., van de Winkel J.G., Kallenberg C.G. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 2001, 22:510-516.
22. Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E., de Haas M. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 1997, 90:1109-1114.
23. Forthal D.N., Gilbert P.B., Landucci G., Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007, 178:6596-6603.
24. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004, 305:872-874.
25. Pandey J.P. Genomewide association studies and assessment of risk of disease. N Engl J Med 2010, 363:2076-2077.
26. Moore J.H., Ritchie M.D. The challenges of whole-genome approaches to common diseases. JAMA 2004, 291:1642-1643. STUDENTJAMA.
27. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796.
28. Taylor R.J., Chan S.L., Wood A., Voskens C.J., Wolf J.S., Lin W., et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009, 58:997-1006.
29. Namboodiri A.M., Pandey J.P. Differential inhibition of trastuzumab and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes. Clin Exp Immunol 2011, 166:361-365.